Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
The Patient
|
January 28, 2025
What Next for the Science of Patient Preference? Interoperability, Standardization, and Transferability
Kevin Marsh, Juan Marcos Gonzalez Sepulveda, Conny Berlin, et al.
BMC Medical Informatics and Decision Making
|
October 6, 2019
Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review
Rosanne Janssens, Isabelle Huys, Eline van Overbeeke, et al.
The Patient
|
March 4, 2021
Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study
A Cecilia Jimenez-Moreno, Eline van Overbeeke, Cathy Anne Pinto, et al.
Chest
|
September 12, 2018
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population
Philip S Wells, Martin H Prins, Jan Beyer-Westendorf, et al.
Frontiers in Pharmacology
|
September 4, 2023
How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action
Rosanne Janssens, Liese Barbier, Mireille Muller, et al.
Vaccine
|
December 22, 2023
The Brighton collaboration standardized module for vaccine benefit-risk assessment
Bennett Levitan, Stephen C Hadler, William Hurst, et al.
Chest
|
June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension
Philip S Wells, Martin H Prins, Bennett Levitan, et al.
Journal of the American Heart Association
|
October 7, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
Gary E Raskob, Walter Ageno, Gregory Albers, et al.
Wellcome Open Research
|
August 16, 2021
A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project
Aura Cecilia Jimenez-Moreno, Cathy Anne Pinto, Bennett Levitan, et al.
Frontiers in Pharmacology
|
December 19, 2019
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
Eline van Overbeeke, Rosanne Janssens, Chiara Whichello, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
The Patient
|
January 28, 2025
What Next for the Science of Patient Preference? Interoperability, Standardization, and Transferability
Kevin Marsh, Juan Marcos Gonzalez Sepulveda, Conny Berlin, et al.
BMC Medical Informatics and Decision Making
|
October 6, 2019
Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review
Rosanne Janssens, Isabelle Huys, Eline van Overbeeke, et al.
The Patient
|
March 4, 2021
Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study
A Cecilia Jimenez-Moreno, Eline van Overbeeke, Cathy Anne Pinto, et al.
Chest
|
September 12, 2018
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population
Philip S Wells, Martin H Prins, Jan Beyer-Westendorf, et al.
Frontiers in Pharmacology
|
September 4, 2023
How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action
Rosanne Janssens, Liese Barbier, Mireille Muller, et al.
Vaccine
|
December 22, 2023
The Brighton collaboration standardized module for vaccine benefit-risk assessment
Bennett Levitan, Stephen C Hadler, William Hurst, et al.
Chest
|
June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension
Philip S Wells, Martin H Prins, Bennett Levitan, et al.
Journal of the American Heart Association
|
October 7, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
Gary E Raskob, Walter Ageno, Gregory Albers, et al.
Wellcome Open Research
|
August 16, 2021
A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project
Aura Cecilia Jimenez-Moreno, Cathy Anne Pinto, Bennett Levitan, et al.
Frontiers in Pharmacology
|
December 19, 2019
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
Eline van Overbeeke, Rosanne Janssens, Chiara Whichello, et al.
Page
of 6